Hepatitis A and B vaccine

AI Revolutionizes HBV Vaccine Development as Global Market Grows at a CAGR of 5.33% - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Technology, Infectious Diseases, Health, Artificial Intelligence, WHO, Bioinformatics, LG Chem, Drug design, Intelligence, Composition, Incidence, Pregnancy, Vaccine, Government, ROW, Prevalence, Indian Immunologicals Limited, GSK plc, Merck, Data science, Mother, Vaccination, Liver cancer, Genomics, Transport, COVAX, COVID-19, Antibody, KM, Microbiology, Machine learning, Biochemistry, Blood, Hepatitis A and B vaccine, Serum, Hepatitis B virus, Public, Sanofi, Hepatitis, Hepatitis B, Immunization, Pediatrics, World Health Organization's response to the COVID-19 pandemic, Compound annual growth rate, HBV, Parent, Cirrhosis, Merck & Co.

The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.

Key Points: 
  • The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.
  • Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines.
  • The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats.
  • The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth.

Global Hepatitis B Virus (HBV) Vaccine Market Report 2023: A $3.04 Billion Market by 2027 from $2.23 Billion in 2021 - Favorable Government Initiatives and Policies Bodes Well for the HBV Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 31, 2023
Infectious Diseases, Pharmaceutical, Health, Cirrhosis, Vaccination, Bill & Melinda Gates Foundation, Vaccine, Hepatitis B vaccine, World Health Organization's response to the COVID-19 pandemic, Hospital, Mono, Merck & Co., Urbanization, Hepatitis, Patient, ROW, HBV, Public Health England, GAVI, Research, Liver cancer, GSK plc, Food, Global Alliance, Risk, WHO, Antibody, Growth, Infection, Drug design, Hepatitis B virus, Prevalence, US Foods, COVID-19, Composition, Hepatitis B, Pharmaceutical industry, Hepatitis A and B vaccine, EU, Immunization

The global hepatitis B virus (HBV) vaccine market was valued at US$2.23 billion in 2021, and is predicted to grow to US$3.04 billion in 2027.

Key Points: 
  • The global hepatitis B virus (HBV) vaccine market was valued at US$2.23 billion in 2021, and is predicted to grow to US$3.04 billion in 2027.
  • Following the approval of the first hepatitis B vaccine in 1981, there has been significant progress in hepatitis B vaccines.
  • In the report, the global hepatitis B virus (HBV) vaccine market is divided into five regions: The US, China, Europen Union, Japan, and ROW.
  • The hepatitis B vaccine market in the US is a significant market, with a high demand for the vaccine due to the ongoing threat of hepatitis B virus (HBV) infection.